KANABO GROUP PLC Logo

KANABO GROUP PLC

Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.

KNB | IL

Overview

Corporate Details

ISIN(s):
GB00BYQCS703
LEI:
213800XPJFSNWJIYKN52
Country:
United Kingdom
Address:
Churchill House, NW4 4DJ London
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kanabo Group PLC is a medical cannabis and wellness company that develops and distributes cannabis-derived products. The company operates a holistic business model, overseeing the entire product lifecycle from research and development to distribution. Its portfolio includes proprietary THC-based medical formulas targeting conditions like CNS disorders, alongside non-THC CBD products for the consumer wellness market. A key innovation is the VapePod®, a medically certified vaporization device designed for precise, metered-dose delivery of cannabis extracts. Kanabo focuses on creating clinically validated, high-quality formulations and has expanded its offerings to include a digital health platform providing patient access to alternative therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-04 08:00
Business and Financial Review
Revenue Growth, Trading and Operational Update
English 19.6 KB
2025-01-06 08:00
Board/Management Information
Directorate Change
English 11.3 KB
2024-11-19 10:55
Report Publication Announcement
The GP Service Wins Award
English 9.2 KB
2024-10-31 10:48
Director's Dealing
Correction Director/PDMR Shareholding
English 27.2 KB
2024-10-29 12:39
Director's Dealing
Director/PDMR Shareholding
English 26.7 KB
2024-09-30 15:50
Earnings Release
Half-year Report
English 307.5 KB
2024-08-28 15:31
Director's Dealing
Director/PDMR Shareholding
English 35.2 KB
2024-06-27 17:49
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
English 23.0 KB
2024-06-04 08:00
Regulatory News Service
Expansion:14 New Clinics Partnership with Treat-It
English 16.6 KB
2024-05-31 11:30
Pre-Annual General Meeting Information
Notice of AGM
English 12.0 KB
2024-04-30 15:15
Annual Report
Annual Financial Report
English 895.4 KB
2024-03-28 08:00
Business and Financial Review
Expansion of Treat It to Mental Health Treatments
English 14.0 KB
2024-03-27 18:11
Major Shareholding Notification
Holding(s) in Company
English 24.2 KB
2024-03-25 08:00
Legal Proceedings Report
Germany Medical Cannabis Legislation Reform
English 14.0 KB
2024-03-18 10:14
Regulatory News Service
Agritec Update
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all KANABO GROUP PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KANABO GROUP PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KANABO GROUP PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.